ライフサイエンスコーパス: vascular graft

1 ice after transplantation of the vessel as a vascular graft.

2 ght carotid artery of mice, which acted as a vascular graft.

3 biological and autologous tissue-engineered vascular graft.

4 need for a readily available, small-diameter vascular graft.

5 r 5 months, had no thrombus in the device or vascular graft.

6 roving anti-neointimal activity of synthetic vascular grafts.

7 searched for cancer patients with prosthetic vascular grafts.

8 inhomogeneous uptake was seen more in Dacron vascular grafts.

9 lusion and neointimal formation of synthetic vascular grafts.

10 s of synthetic hemodialysis grafts and other vascular grafts.

11 from thrombi forming within collagen-coated vascular grafts.

12 cus aureus causes very serious infections of vascular grafts.

13 llagen fibrils to guide cell organization in vascular grafts.

14 ce for the construction of tissue-engineered vascular grafts.

15 y and reduces the rejection rate of lung and vascular grafts.

16 and the next generation of tissue-engineered vascular grafts.

17 iovenous fistulae, particularly in synthetic vascular grafts.

18 ition and fibrin accumulation on segments of vascular graft and endarterectomized aorta in vivo.

19 Variability arises as to whether to use a vascular graft and where on the portal system to attach

20 nclude rapid endothelialization of synthetic vascular grafts and dialysis fistulas.

21 engineered blood vessels (TEBV) can serve as vascular grafts and may also play an important role in t

22 t from numerous investigations, drug-eluting vascular grafts and stents have not solved the main prob

23 cer therapy, wound healing, and drug-eluting vascular grafts and stents.

24 ellent patency of small-diameter nanofibrous vascular grafts, and the unique antithrombogenic propert

25 te into endothelium, and implanted synthetic vascular grafts are seeded by host SMCs and endothelium.

26 ion of the autograft root within a synthetic vascular graft, are known, the Ross procedure should not

27 Here, we used tissue-engineered vascular grafts as a model to demonstrate the potential

28 s (ECs) lining surgically implanted arterial vascular grafts (AVGs).

29 et and 125I-fibrin deposition on segments of vascular graft but detectably decreased 111In-platelet a

30 , macrophages, and infiltrating cells in the vascular grafts, but were independent of hemodynamics an

31 nique was employed to construct a functional vascular graft by immobilization of galactosidase on the

32 ition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte a

33 Synthetic vascular grafts cannot be used in small vessels because

34 were seeded onto collagen-coated segments of vascular graft (collagen segments) and exposed overnight

35 We developed a tissue-engineered vascular graft composed of biodegradable scaffold seeded

36 fibrin deposition for segments of prosthetic vascular graft, deployed endovascular metallic stents, a

37 Application of a tissue-engineered vascular graft for small-diameter vascular reconstructio

38 applications in improving tissue-engineered vascular grafts for cardiovascular therapies with small

39 sceptibility and in developing bioengineered vascular grafts for regenerative medicine.

40 roach may be useful to develop new cell-free vascular grafts for treatment of vascular diseases.

41 tails extending downstream from segments of vascular graft from 1.38+/-0.41 x 10(9) platelets in con

42 Here we present an 'off-the-shelf' vascular graft grown from donor fibroblasts in a fibrin

43 oiliac aneurysms with traditional prosthetic vascular grafts has been shown to be effective.

44 he heart through a native artery or a patent vascular graft have a markedly reduced risk of periopera

45 teriosclerosis, renal failure, diabetes, and vascular graft implants.

46 .min-1 immediately upstream from a polyester vascular graft in the unheparinized baboon circulatory s

47 rate derivative are employed as coatings for vascular grafts in sheep.

48 chment and retention of endothelial cells on vascular grafts in vivo, which opens new avenues of rese

49 years with prosthetic valve endocarditis or vascular graft infection due to M. chimaera, which becam

50 red in 12 patients with endocarditis, 2 with vascular graft infection, and 2 with complicated bactere

51 T is of value in the diagnosis of prosthetic vascular graft infection, but potential pitfalls related

52 therapy control in patients with prosthetic vascular graft infections (PVGIs).

53 of this study was to set up a mouse model of vascular graft infections that closely mimics the human

54 by innate immune cell subsets also promotes vascular graft injury.

55 reduced fibrin formation in collagen-coated vascular grafts inserted into arteriovenous shunts in ba

56 metallic stents or thrombogenic segments of vascular graft interposed in exteriorized long-term arte

57 Essential to tissue-engineered vascular grafts is the formation of a functional endothe

58 strategy to improve re-endothelialization of vascular grafts, maintaining or enhancing mechanical pro

59 as developed to produce arbitrary lengths of vascular graft material from smooth muscle and endotheli

60 thrombus on metallic stents and segments of vascular graft (P<.001 in all cases for 8-mg/kg doses).

61 By using aortopulmonary vascular graft placement in the fetal lamb (shunt lambs)

62 Using a vascular-graft rat model, we show that RIP, applied loca

63 d the effects of PPARgamma agonists on human vascular graft rejection using a model in which human ar

64 onses and may be useful for the treatment of vascular graft rejection.

65 went in utero placement of an aortopulmonary vascular graft (shunt) and were studied 8 weeks after sp

66 ivity when coated on a normally thrombogenic vascular graft situated in an arteriovenous shunt in a b

67 ity to vascular scaffolds, optimize internal vascular graft surface and even help to direct the diffe

68 endothelial cells and thereby confer longer vascular-graft survival.

69 he first clinical trial of tissue-engineered vascular grafts (TEVGs) identified stenosis as the prima

70 ninvasive MR monitoring of tissue-engineered vascular grafts (TEVGs) in vivo using cells labeled with

71 lls seeded onto functional tissue-engineered vascular grafts (TEVGs) through serial imaging.

72 ls (BMCs) are the earliest tissue-engineered vascular grafts (TEVGs) to be used clinically.

73 rial evaluating the use of tissue-engineered vascular grafts (TEVGs) was stenosis.

74 the long-term efficacy of tissue-engineered vascular grafts (TEVGs).

75 Thus, we create an enzyme-functionalized vascular graft that can catalyze prodrug to release NO l

76 ial progenitor cells to provide a biological vascular graft that resists both clotting and intimal hy

77 es for the construction of tissue-engineered vascular grafts that are nonthrombogenic and have long-t

78 of relaparotomy were hemorrhage (59.3%) and vascular graft thrombosis (22.2%).

79 Vascular graft thrombosis and bleeding are two major iss

80 he secondary endpoints were the incidence of vascular graft thrombosis, postoperative sepsis, patient

81 %) experienced a symptomatic or asymptomatic vascular graft thrombosis.

82 iscussed include endothelial cell seeding of vascular grafts, tissue-engineered vascular conduits, ge

83 tissues, including multilayered skin, bone, vascular grafts, tracheal splints, heart tissue and cart

84 ich potentially could lead to drug-entrapped vascular grafts: urokinase-type plasminogen activator wa

85 homologous endarterectomized aorta (EA) and vascular graft (VG) interposed in arteriovenous femoral

86 homologous endarterectomized aorta (EA) and vascular graft (VG) interposed in arteriovenous femoral

87 Completely autologous tissue-engineered vascular grafts were grown in culture supplemented with

88 The functional vascular grafts were implanted into the rat abdominal ao

89 tissue engineered autologous small-diameter vascular graft, which can function in arterial high pres

90 s components of the mechanical properties of vascular grafts, which is positively correlated with the

91 gnetic forces can be used to rapidly cover a vascular graft with paramagnetically labeled cells.

92 The development of a living, autologous vascular graft with the ability to grow holds great prom

93 Seeding of small-diameter vascular grafts with endothelial cells (ECs) genetically